Clinical Trial Update: Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy [Phase 3]

View source ↗

Summary

Phase 3 trial of Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Istituto Clinico Humanitas | Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 3 | Status: COMPLETED